Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 1
2012 2
2014 1
2015 2
2016 5
2017 25
2018 36
2019 27
2020 23
2021 13
2022 8
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Valbenazine.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 37748010 Free Books & Documents. Review.
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recommends that breastfeeding be avoided during valbenazine therapy and for 5 days after the final dose....
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recom …
Valbenazine for Tardive Dyskinesia.
Freudenreich O, Remington G. Freudenreich O, et al. Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Clin Schizophr Relat Psychoses. 2017. PMID: 28742396 Review.
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperk …
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modi …
Valbenazine for the Treatment of Adults with Tardive Dyskinesia.
Gupta H, Moity AR, Jumonville A, Kaufman S, Edinoff AN, Kaye AD. Gupta H, et al. Health Psychol Res. 2021 Jun 18;9(1):24929. doi: 10.52965/001c.24929. eCollection 2021. Health Psychol Res. 2021. PMID: 35106396 Free PMC article. Review.
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches. ...Once symptom onset has occurred, these movement abno …
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive …
Valbenazine for the treatment of tardive dyskinesia.
Müller T. Müller T. Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12. Expert Rev Neurother. 2017. PMID: 28971695 Review.
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine ameliorated the severity of tardive dyskinesia. The chiral purity of valbenazine circumvents generation of the (-)alpha and (+) an …
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine …
Valbenazine: First Global Approval.
Kim ES. Kim ES. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Drugs. 2017. PMID: 28578484 Review.
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. ...This article summarizes the milestones in the develo …
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by N …
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo). ...No suicidal behaviour or …
Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo …
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. Hauser RA, et al. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. Am J Psychiatry. 2017. PMID: 28320223 Clinical Trial.
Valbenazine was generally well tolerated, and psychiatric status remained stable. Longer trials are necessary to understand the long-term effects of valbenazine in patients with tardive dyskinesia....
Valbenazine was generally well tolerated, and psychiatric status remained stable. Longer trials are necessary to understand the long- …
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F, Luther K, Talreja O. Khorassani F, et al. Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299. Am J Health Syst Pharm. 2020. PMID: 31974564 Review.
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment of tardive dyskinesia (TD). SUMMARY: A literature search was conducted to gather relevant data regarding the use of valbenazine and de …
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment o …
Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
Touma KTB, Scarff JR. Touma KTB, et al. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-16. Innov Clin Neurosci. 2018. PMID: 30013814 Free PMC article. Review.
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treat …
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or disconti …
Clinical development of valbenazine for tics associated with Tourette syndrome.
Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E. Farber RH, et al. Expert Rev Neurother. 2021 Apr;21(4):393-404. doi: 10.1080/14737175.2021.1898948. Epub 2021 Apr 1. Expert Rev Neurother. 2021. PMID: 33682568 Review.
While there was a trend in the 6 completed trials toward greater improvement in valbenazine-treated versus placebo subjects on the primary efficacy endpoint (Yale Global Tic Severity Scale Total Tic Score), this difference did not reach statistical significance. Valbena …
While there was a trend in the 6 completed trials toward greater improvement in valbenazine-treated versus placebo subjects on the pr …
150 results